Relative contribution of incretins to the glucose lowering effect of DP IV inhibitors in type 2 diabetes mellitus (T2DM).
Hinke
Simon A
SA
Department of Metabolism and Endocrinology, Diabetes Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium. shinke@vub.ac.be
Pederson
Raymond A
RA
McIntosh
Christopher H S
CH
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D002241:Carbohydrates / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000201:enzymology* / Q000628:therapy; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D004359:Drug Therapy, Combination; D005749:Gastric Inhibitory Polypeptide / Q000737:chemistry / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007408:Intestinal Absorption; D015842:Serine Proteinase Inhibitors / Q000378:metabolism* / Q000627:therapeutic use; D015398:Signal Transduction / Q000502:physiology
D001786:Blood Glucose; D002241:Carbohydrates; D007328:Insulin; D015842:Serine Proteinase Inhibitors; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D018819:Dipeptidyl Peptidase 4